ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1214

In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1391

Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1422

Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1449

Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1489

Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1244

Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1545

Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1373

Increased Patient Contact May Mitigate Flares Among jSLE Patients

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1286

Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1488

Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1290

Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1399

Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1129

Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1131

Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1406

Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].